This Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $782,916 to support research and development of a novel therapy to treat fecal incontinence and fecal urgency. The funded work by Dignify Therapeutics, LLC aims to inhibit colorectal afferent terminals, which may effectively prevent or reduce symptoms of fecal incontinence, fecal urgency,...
This $862,002 Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) supports an in-depth investigation of mechanisms to enhance the motor function of fecal continence muscles in order to improve fecal incontinence. The key research objectives are to: 1) characterize the fatigability of continence muscles across age and sex, and 2) determine the effect of...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $584,750 Project Grant (R43DK141382) to Foli Bio Inc. under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847). The goal of this 1-year project is to validate the utility of Foli Bio's proprietary "EXFO-SEQ" technology, which enables sensitive and quantitative sequencing of the RNA content (exfoliome) exfoliated from intestinal cells into stool samples. This...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $324,678 to Lumina Medical LLC to develop an innovative motorized, girth-adjustable anal dilator device. The device aims to improve patient adherence to anal dilation treatment for conditions such as anismus and anal stenosis by enabling gentle, incremental stretching and...
This federal Project Grant award from the National Institute of Child Health and Human Development (CFDA 93.865 - Child Health and Human Development Extramural Research) provides $215,250 to the Veterans Medical Research Foundation of San Diego to conduct research on preventing anal sphincter dysfunction after childbirth-related neuromuscular injury. The key objectives of the research are to evaluate the efficacy of a novel brain-derived neurotrophic factor (BDNF) sustained-release...
This Project Grant award from the National Institute of Child Health and Human Development (NICHD) under the Child Health and Human Development Extramural Research program (CFDA 93.865) will fund research to investigate gastrointestinal dysfunction in Down syndrome. The $232,875 award to Virginia Commonwealth University will support a 2-year study to test the hypothesis that trisomy 21 in Down syndrome leads to altered voltage-gated calcium currents in smooth muscle of the distal colon,...
This federal Project Grant award from the National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847), provides $662,832 to Actuated Medical, Inc. to develop and demonstrate the feasibility of a photoacoustic visualizer (PAV) system. The PAV system aims to improve the implantation accuracy of sacral neurostimulation (SNS) leads, which are used to treat bladder or bowel incontinence. The...
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK) awarded a $582,825 Project Grant under the Diabetes, Digestive, and Kidney Diseases Extramural Research program (CFDA 93.847) to Epic Nutrition For Y LLC. The grant supports a two-year research project to investigate the long-term safety and efficacy of a novel probiotic strain, Clostridium cochlearium 2316 (CC), in mitigating obesity and insulin resistance in diet-induced obese mice. The key objectives are to 1)...
This Project Grant awarded by the National Cancer Institute (NCI), under the federal Cancer Detection and Diagnosis Research program (CFDA 93.394), provides $399,789 to Ergami Endoscopy, Inc. to develop an automated robotic flexible overtube device capable of blind insertion during colonoscopy procedures. The device aims to reduce physician injuries, improve productivity, and decrease patient pain/sedation requirements for the over 16 million colonoscopies performed annually in the U.S. Key...
This Project Grant award from the National Cancer Institute (NCI) under the Cancer Treatment Research program (CFDA 93.395) provides $838,162 to Averto Medical Inc. to conduct a clinical trial of the Coloseal ICD System, a novel medical device designed to eliminate the need for temporary ostomy surgeries in rectal cancer patients. The Coloseal ICD System is a minimally-invasive technology that can safely replace the function of temporary ostomies, which are commonly required for rectal cancer...
DEFECATION MECHANISMS AND SUBTYPING OF CONSTIPATION PATIENTS WITH FECOBIONICS - ABSTRACT CHRONIC CONSTIPATION (CC) IS A COMMON CONDITION THAT AFFECTS UP TO 25% OF THE POPULATION IN NORTH AMERICA WITH RISING INCIDENCE THAT POSES A MAJOR BURDEN ON THE HEALTHCARE COST. THE PATHOPHYSIOLOGY OF THIS CONDITION IS POORLY UNDERSTOOD AND CONSEQUENTLY THERE ARE INADEQUATE TREATMENTS. THE SIGNIFICANT PROBLEMS ARE, 1) INCOMPLETE UNDERSTANDING OF THE DEFECATION REFLEX AND 2) LACK OF PHYSIOLOGICALLY RELEVANT AND PRACTICAL DIAGNOSTIC TEST FOR IDENTIFYING THE UNDERLYING MECHANISM(S). CURRENT DIAGNOSTIC TESTS PROVIDE INCOMPLETE AND OFTEN CONFLICTING INFORMATION. NOT SURPRISINGLY, RESULTS OF THESE TESTS CORRELATE POORLY WITH SYMPTOMS AND TREATMENT OUTCOMES. OUR OBJECTIVE IS TO PROVIDE AN IMPROVED UNDERSTANDING OF THE CONTINENCE MECHANISMS AND DEFECATION PATTERNS IN HEALTHY SUBJECTS AND PATIENTS WITH CC USING A NOVEL FECOBIONICS DEVICE FOR MAPPING THE GEOMETRIC AND MANOMETRIC PROFILES DURING EVACUATION. FECOBIONICS IS AN ELECTRONIC SIMULATED STOOL THAT HAS THE CONSISTENCY AND SHAPE OF NORMAL STOOL. THE DEVICE RECORDS PRESSURES, CROSS-SECTIONAL AREA, ORIENTATION, BENDING, SHAPE, AND VISCOELASTIC PROPERTIES OF THE RECTUM AND ANAL CANAL SIMULTANEOUSLY. OUR CENTRAL HYPOTHESIS IS THAT RECTAL PERISTALSIS IS A KEY COMPONENT OF THE DEFECATORY REFLEX WHICH IS NOT ASSESSED IN THE CURRENT PARADIGM OF DIAGNOSTIC TESTING. THE NOVEL FECOBIONICS DEVICE WILL MIMIC THE NATURAL DEFECATION AND PROVIDE NEW MECHANISTIC INSIGHTS INTO THE ANORECTAL PHYSIOLOGY AND PATHOPHYSIOLOGY TO FACILITATE THE DEVELOPMENT OF NEW TREATMENTS FOR CC. FECOBIONICS CAN PROVIDE COMPLETE PICTURE OF THE NORMAL DEFECATION PATTERN ("SIGNATURES") THAT INCLUDES RECTAL PERISTALTIC REFLEX, DEFORMABILITY OF THE DEVICE AND DISTENSIBILITY OF THE ANAL SPHINCTERS IN HEALTHY SUBJECTS AND PATIENTS WITH VARIOUS SUBTYPES OF CC. THE SPECIFIC AIMS ARE AS FOLLOWS: 1) STUDY THE DEFECATION DYNAMICS IN NORMAL CONTROL SUBJECTS USING FECOBIONICS. WE WILL ESTABLISH THE ROLE OF RECTAL CONTRACTION/PERISTALSIS IN THE NORMAL EVACUATION PROCESS. 2) DEFINE THE DEFECATORY PATTERNS IN PATIENTS WITH CC ASSOCIATED WITH DEFECATORY DISORDERS. WE WILL DETERMINE IF ABNORMALITIES OF RECTAL CONTRACTION CONTRIBUTE TO THE CC. 3) USE A MATHEMATICAL MODEL OF ANORECTAL PASSAGE OF FECOBIONICS FOR ENHANCED UNDERSTANDING OF THE NORMAL AND ABNORMAL DEFECATORY PATTERNS, INCLUDING THE LENGTH-TENSION PROPERTIES OF THE RECTUM AND ANAL SPHINCTER MUSCLES. OUR PROPOSAL SEEKS TO SHIFT CURRENT CC RESEARCH BY PROVIDING A STOOL SURROGATE FOR EXAMINING THE PHYSIOLOGIC PARAMETERS OF DEFECATION REFLEX USING A NOVEL DEVICE THAT WILL RECORD, PRESSURE, DEFORMABILITY, BIOMECHANICS, VECTORAL AND TOPOGRAPHIC CHANGES IN THE RECTUM AND ANAL CANAL. THE NOTED PARAMETERS WILL BE RECORDED USING A WIRELESS FECOBIONICS DEVICE THAT CAN EXAMINE IN DETAIL THE MECHANISTIC UNDERPINNINGS (STRESS AND DEFORMATION) OF DEFECATION REFLEX/PROCESS IN HEALTH AND DISEASE. THE IMPACT OF THIS PROJECT IS THAT IT ASSESSES A NOVEL, SAFE, LOW COST, LESS INVASIVE, LOW-RISK, RADIATION-FREE DEVICE IN ITS ABILITY TO PROVIDE BETTER UNDERSTANDING OF EVACUATION AND CONTINENCE MECHANISMS AND THEREBY FACILITATE FUTURE DEVELOPMENT OF INNOVATIVE THERAPIES. THE IMPROVEMENT CAN LEAD TO IMPROVEMENT IN DIAGNOSTIC AND THERAPEUTIC MODALITIES AND REDUCE HEALTHCARE COSTS ASSOCIATED WITH ANORECTAL DISORDERS.